Biotech Business - November 15, 2023
Neogap Therapeutics raises SEK 83 million
The company has raised SEK 54 million in a new share issue and has also been granted an additional SEK 29 million in innovation funding from the EU. The company has strengthened its financial position through a new share issue, with the investment company Sciety and investment syndicate Sciety Venture Partners. Alongside this, the company […]
Biotech Business - November 8, 2023
Modus Therapeutics raises SEK 40.3 million
The Board of Directors of Modus Therapeutics Holding has resolved to carry out a new issue of up to 20,125,060 shares with pre-emptive rights for the company’s shareholders, as well as a directed issue of 10,156,569 shares through the offsetting of loans from Karolinska Development AB amounting to approximately SEK 20.3 million. The Rights Issue […]
Biotech Business - November 8, 2023
Medivir raises approximately SEK 148 million
The Board of Directors of Medivir has resolved to carry out a new issue of shares with preferential rights for existing shareholders of approximately SEK 148 million. An extraordinary general meeting is proposed to approve the Board of Directors’ resolution on the Rights Issue. The EGM is set to be held on 1 December 2023. […]
Biotech Business - November 8, 2023
New study confirms HiloProbe’s ColoNode kit
The results of a prospective multicenter study conducted in collaboration with Umeå University and eight Swedish hospitals have been published in the International Journal of Cancer. The study shows that HiloProbe’s ColoNode kit can identify more patients at risk of tumor recurrence following surgery compared to today’s standard method, states the company. “ColoNode can both […]
Biotech Business - November 7, 2023
Abera Bioscience secures GBP 1.8 million funding
The company has announced the receipt of a funding award from the UK Vaccine Network program. This research program is funded by the Department of Health and Social Care as part of the UK Vaccine Network (UKVN), a UK Aid programme to develop vaccines for diseases with epidemic potential in low and middle-income countries (LMICs). […]
Agreement - November 1, 2023
AstraZeneca enters agreement with Cellectis
AstraZeneca has announced a collaboration and investment agreement with the French clinical-stage biotechnology company Cellectis to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases. Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis gene editing technologies and manufacturing capabilities, to design […]
